Role of clusterin in the brain vascular clearance of amyloid-β
- 15 August 2017
- journal article
- editorial
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (33) , 8681-8682
Abstract
Alzheimer’s disease (AD) is the most common form of dementia, characterized by neurovascular dysfunction, elevated brain parenchymal and vascular amyloid-β (Aβ) levels, tau pathology, and neuronal loss (1, 2). Faulty transvascular clearance of brain Aβ across the blood–brain barrier (BBB) plays an important role in Aβ accumulation in the brain, both in human AD and animal models (1⇓⇓–4). Normally, transvascular brain-to-blood transport across the BBB clears most of Aβ from brain (∼85%), whereas the interstitial fluid (ISF) bulk flow along perivascular spaces removes the remaining smaller fraction of ∼15% of Aβ (5). The two major apolipoproteins in brain, apolipoprotein E (APOE) and apolipoprotein J (APOJ), also known as clusterin (CLU), interact with Aβ and regulate its clearance from brain (1, 2) (Fig. 1). Specifically, Aβ is cleared across the BBB as a free peptide and/or bound to apolipoproteins E2 and E3, but not E4, via endothelial low-density lipoprotein receptor-related protein 1 (LRP1), whereas CLU binds Aβ and mediates its clearance across the BBB via low-density lipoprotein-related protein 2 (LRP2; also known as megalin and gp330) (2, 4). Peripheral Aβ reenters the brain by the receptor for advanced glycation end products (RAGE) (6). In PNAS, Wojtas et al. (7) explore the effect of endogenous murine Clu deficiency on Aβ pathology. The neurovascular unit includes neurons, astrocytes, mural cells, and endothelial cells. The type of mural cell varies along the vascular tree, with smooth muscle cells circumventing arteries and arterioles, …Keywords
Funding Information
- HHS | NIH | National Institute on Aging (P50AG005142, R01AG023084, P01AG052350, RO1NS100459)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01NS034467, R01NS090904)
- Fondation Leducq (Fondation Leducq Transatlantic Network of Excellence for the Study of Perivascular Spaces in Small V)
- Alzheimer's Association (509279)
This publication has 23 references indexed in Scilit:
- Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathwaysProceedings of the National Academy of Sciences, 2017
- Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearanceNature Neuroscience, 2015
- Clusterin facilitates in vivo clearance of extracellular misfolded proteinsCellular and Molecular Life Sciences, 2011
- Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer diseaseNeurobiology of Disease, 2006
- Apolipoprotein E Markedly Facilitates Age-Dependent Cerebral Amyloid Angiopathy and Spontaneous Hemorrhage in Amyloid Precursor Protein Transgenic MiceJournal of Neuroscience, 2003
- Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2002
- Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrierJournal of Clinical Investigation, 2000
- Interaction of Apolipoprotein J-Amyloid β-Peptide Complex with Low Density Lipoprotein Receptor-related Protein-2/MegalinJournal of Biological Chemistry, 1997
- Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer′s Amyloid βBiochemical and Biophysical Research Communications, 1994